A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

BACKGROUND: We conducted an open-label, randomized, two-arm multi-center study to assess the efficacy and safety of paclitaxel versus paclitaxel + sorafenib in patients with locally advanced or metastatic HER2-negative breast cancer. METHODS: Patients were randomly assigned to receive either paclita...

Descripción completa

Detalles Bibliográficos
Autores principales: Decker, Thomas, Overkamp, Friedrich, Rösel, Siegfried, Nusch, Arnd, Göhler, Thomas, Indorf, Martin, Sahlmann, Jörg, Trarbach, Tanja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526236/
https://www.ncbi.nlm.nih.gov/pubmed/28743247
http://dx.doi.org/10.1186/s12885-017-3492-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526236/
https://www.ncbi.nlm.nih.gov/pubmed/28743247
http://dx.doi.org/10.1186/s12885-017-3492-1

Ejemplares similares